载药微球子宫动脉栓塞联合静脉化学治疗晚期宫颈癌伴阴道出血的疗效和安全性

The curative effect and safety of drug-eluting beads transarterial chemoembolization combined with intravenous chemotherapy in treating advanced cervical cancer associated with vaginal bleeding

目的 探讨载药微球经子宫动脉化疗栓塞联合静脉化疗局部晚期宫颈癌伴阴道出血的疗效和安全性。方法 回顾性分析2015年至2020年38例CalliSpheres载药微球(加载顺铂70 mg/m^(2))经子宫动脉栓塞联合静脉化疗(紫杉醇135 mg/m^(2))局部晚期宫颈癌伴阴道不规则出血患者的临床资料。评价近期疗效、手术切除率、长期疗效及不良反应。结果 经1次子宫动脉栓塞治疗后,阴道出血全部停止。治疗后1个月有效率为68.4%(26/38),肿瘤控制率为100.0%(38/38),手术切除率为94.7%(36/38)。中位生存时间为68.4个月,1、3、5年生存率分别为97.4%、78.6%、64.6%。未见特殊不良反应发生。结论 载药微球经子宫动脉栓塞联合静脉化学治疗局部晚期宫颈癌伴阴道出血患者疗效显著,不良反应轻。

Objective To evaluate the curative effect and safety of drug-eluting beads transarterial chemoembolization(DEB-TACE) combined with intravenous chemotherapy in treating advanced cervical cancer associated with vaginal bleeding. Methods The clinical data of a total of 38 patients with advanced cervical cancer associated with vaginal bleeding, who received CalliSpheres DEB-TACE(loaded with cisplatin 70 mg/m^(2))combined with intravenous chemotherapy(paclitaxel 135 mg/m^(2)) between 2015 and 2020,were retrospectively analyzed. The short-term efficacy, surgical resection rate, long-term efficacy and adverse reactions were evaluated. Results After one treatment of uterine artery embolization, vaginal bleeding stopped in all the 38patients. The one-month effective rate was 68.4%(26/38), the tumor control rate was 100.0%(38/38), and the surgical resection rate was 94.7%(36/38). The median survival time was 68.4 months, and the 1-, 3-and5-year survival rates were 97.4%,78.6% and 64.6%, respectively. No special adverse reactions occurred.Conclusion For the treatment of patients with locally-advanced cervical cancer associated with vaginal bleeding, DEB-TACE combined with intravenous chemotherapy has significant curative effect with mild adverse reactions.